Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Roflumilast Cream in Pediatric Atopic Dermatitis
NCT04156191Phase 1Completed
- Sponsor
- Arcutis Biotherapeutics
- Start
- Dec 2019
- Primary completion
- May 2023
- Countries
- 1
01
Overview
Phase 1, open-label trial of roflumilast vehicle cream in atopic dermatitis (AD) (8 arms), sponsored by Arcutis Biotherapeutics. Primary endpoints: Maximum Plasma Concentration at 4 weeks, Area Under the Curve at 4 weeks and 1 more. Started Dec 2019; status: completed.
02
Drugs
roflumilast vehicle cream
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04156191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04156191.